Skip to main content
. 2020 Jun 9;9(6):1794. doi: 10.3390/jcm9061794

Table 6.

Descriptive characteristics of patients with major bleeding events.

Study Patients
(n = 16)
Sex Age ACHD type NOAC * Bleeding Location Indication CHA2D2-VASC HAS-BLED Risk Factors and Comorbidities
Yang [28] 1 F 56 Fontan Apixaban Gastrointestinal AtrialArrhythmia 2 1 Mitral Regurgitation
Yang [28] 2 F 71 PAPVC Rivaroxaban Gastrointestinal AtrialArrhythmia 3 1 Tricuspid Regurgitation
Yang [28] 3 F 23 CoA Rivaroxaban Menorrhagia AtrialArrhythmia 2 0 Bioprosthetic AVand PV
Yang [28] 4 F 42 Eisenmenger Rivaroxaban Menorrhagia Pulmonary Embolism 3 2 -
Yang [28] 5 F 41 Fontan Apixaban Menorrhagia Atrial Arrhythmia 4 0 Mitral Valve Regurgitation
Yang [28] 6 M 80 ToF Apixaban Hematuria AtrialArrhythmia 4 1 Pulmonary Stenosis
Yang [28] 7 F 67 Fontan Rivaroxaban Menorrhagia AtrialArrhythmia 2 2 -
Pujol [29] 8 M 59 PFO Apixaban 5 mg b.i.d Cranial PTP 3 3 Aspirin Arterial Hypertension
Pujol [29] 9 F 48 TGA-Mustard Rivaroxaban 20 mg q.d Cranial PTP 2 0 Oral Contraception
Pujol [29] 10 M 26 PA + VSD, PH Deletion 22q11 Rivaroxaban 10 mg q.d Gastrointestinal PTP 1 3 Renal Insufficiency, Cyanosis, Bleeding under VKA
Pujol [29] 11 M 65 ASD Apixaban 2.5 mg b.i.d Intraoccular PTP 3 2 Arterial Hypertension Smoker
Pujol [29] 12 F 44 PA + VSDPAH Apixaban 5 mg b.i.d Intraarticular PTP 2 0 Renal Insufficiency, Diabetes Mellitus
Pujol [29] 13 F 46 Marfan Rivaroxaban 20 mg q.d Intraarticular PTP 2 0 Smoker
Pujol [29] 14 F 43 ASD Rivaroxaban 20 mg q.d Intramuscular PTP 1 0 -
Pujol [29] 15 F 34 PFO Edoxaban 60 mg q.d Vaginal PTP 3 3 Bleeding under VKA
Pujol [29] 16 F 42 VSD (corrected) Rivaroxaban 20 mg q.d Vaginal PTP 1 0 -

Abbreviations: M: Male; F: Female; PAPVC: partial anomalous pulmonary venous connection; CoA: coarctation of the aorta; ToF: tetralogy of fallot; PFO: persistent foramen ovale; VSD: ventricular Septal defect; ASD: atrial septal defect; PTP: primary thromboprophylaxis; TGA: transposition of great arteries; AV: aortic valve; PV: pulmonary valve; b.i.d: twice a day; q.d; once a day. * NOAC dose indicated where reported.